LABP(Delisted)
Landos Biopharma·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 0
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LABP
Landos Biopharma, Inc.
A clinical-stage biopharmaceutical company that develops novel, oral medicines for patients with autoimmune diseases
P.O. Box 11239, Blacksburg, Virginia 24062
--
Landos Biopharma, Inc., incorporated in Delaware in January 2017, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of oral therapies for patients with autoimmune diseases. The company's core expertise is in the development of immune and metabolic therapy candidates for new pathways. Based on the understanding of the role of cellular metabolic pathways in regulating inflammatory responses, the company aims to inhibit these inflammatory responses by altering the metabolic processes of target cells.
Company Financials
EPS
LABP has released its 2023 Q4 earnings. EPS was reported at -0.99, versus the expected -0.91, missing expectations. The chart below visualizes how LABP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
